Here are five key observations:
1. The China spinal fusion market is expected to have double-digit growth over the next few years because technology advancements and minimally invasive techniques are allowing more people to undergo spinal fusions. The reduced costs also make the procedure more accessible to a greater patient volume.
2. The China spinal fusion market is in a new product development phase with technical advancement occurring more rapidly due to a greater demand for spinal fusion. The device manufacturing companies are raising respective market share with “aggressive marketing activities” and increasing research and development.
3. There is an increase in the aging population in China as well as spine-related disease and injury, which contributes to the higher demand for fusion. But the population is price-sensitive and responsive to treatment prices that are anticipated to drip in the near future due to increased competition.
4. Economic growth in China and government initiatives for access to healthcare both bring spinal fusion to the rural population. Minimally invasive procedures make spine surgery accessible to these patients.
5. There are challenges to the market, including reimbursement cuts and heavy government regulations. Additionally, the China spinal infusion market is growing and other treatment methods such as artificial disc replacement and posterior dynamic stabilization are growing in popularity.
6. Key players in the market include Trauson, DePuy Synthes, Zimmer Biomet, NuVasive, Stryker, Orthofix, B. Braun Aesculap and Weigao Orthopaedic Device.
More articles on orthopedic devices:
5 key notes on minimally invasive SI joint fusion implant survivorship
5 key trends driving the spine & orthopedic device market development today
8 new device launches and releases
